HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

Rhea-AI Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced their participation in two virtual investor conferences: the SVB Leerink Oncology 1x1 Day on November 19, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The company is focused on developing a new class of immunotherapeutics using their proprietary arenavirus platform. Their ongoing research includes a Phase 2 clinical trial for a CMV vaccine for kidney transplant patients and collaborations with Gilead Sciences for HIV and Hepatitis B treatments.

NEW YORK and VIENNA, Austria, Nov. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in two upcoming virtual investor conferences:

• The SVB Leerink Oncology 1x1 Day, November 19, 2020
• The Piper Sandler 32^nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020

HOOKIPA will participate in virtual one-on-one meetings during these events.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave^®) and replicating (TheraT^®), induce robust antigen-specific CD8⁺ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8⁺ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media	Investors
Nina Waibel	Matt Beck
Senior Director - Communications	Executive Director - Investor Relations
nina.waibel@hookipapharma.com	matthew.beck@hookipapharma.com

FAQ

What events will HOOKIPA participate in during November 2020?

HOOKIPA will participate in the SVB Leerink Oncology 1x1 Day on November 19, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020.

What is HOOKIPA's proprietary platform used for?

HOOKIPA's proprietary arenavirus platform is used to develop a new class of immunotherapeutics that aim to reprogram the body's immune system.

What clinical trials is HOOKIPA currently conducting?

HOOKIPA's non-replicating prophylactic CMV vaccine is in a Phase 2 clinical trial for patients awaiting kidney transplantation.

What partnerships does HOOKIPA have for research purposes?

HOOKIPA has entered into a collaboration with Gilead Sciences to research arenavirus-based functional cures for HIV and chronic Hepatitis B.

What are the lead oncology product candidates of HOOKIPA?

HOOKIPA's lead replicating arenavirus oncology product candidates are HB-201 and HB-202, currently in development for treating Human Papilloma Virus 16-positive cancers.